S&P Global Ratings upgraded Teva Pharmaceutical Industries’ long-term issuer credit rating to 'BBB-' from 'BB+' with a stable outlook. This milestone grants Teva investment-grade status from all major rating agencies, following previous upgrades by Fitch and Moody's. The rating reflects the company's successful 'Pivot to Growth' strategy and significant debt reduction.
UBS Group increased its price target for Teva to $48.00 from $42.00 and maintained a Buy rating. Ten analyst firms currently hold a consensus Moderate Buy rating on the company.
Pipeline advancements further support the positive outlook. Teva recently reported promising Phase 2a results for its anti-IL-15 antibody, a treatment targeting celiac disease.